Vor Biopharma Inc. - Common Stock (VOR)

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

The Dow Jones futures were up by 0.11% while the S&P 500 futures were up 0.04%.

Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA nephropathy.

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints.

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing.

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease.